La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Radiopharm Theranostics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Radiopharm Theranostics..

Radiopharm Theranostics (NASDAQ:RADX) Azioni, Catena delle Opzioni

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

RADX

SRDX

Analisi dei titoli più promettenti: quali opportunità si celano dietro i segnali di ipervenduto nel settore sanitario?

Settore sanitario: 3 azioni da non farsi scappare in questo trimestre

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics Ltd

Health Care

Press Releases

General

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)

Contracts

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

Management

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Earnings

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

AlphaTON Capital

BioAtla

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Equillium

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Lantern Pharma

MAIA Biotechnology

Medicus Pharma

MediciNova

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Radiopharm Theranostics

Serina Therapeutics

Skye Bioscience

Senti Biosciences

vTv Therapeutics Inc. - Class A Common Stock

Comments

Radiopharm Theranostics

Radiopharm Theranostics (RADX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO